[HTML][HTML] Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
H Yokouchi, K Yamazaki, I Kinoshita, J Konishi… - BMC cancer, 2007 - Springer
Background Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
[PDF][PDF] Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
H Yokouchi, K Yamazaki, I Kinoshita, J Konishi… - BMC Cancer, 2007 - Citeseer
Background: Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
[HTML][HTML] Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
H Yokouchi, K Yamazaki, I Kinoshita, J Konishi… - BMC Cancer, 2007 - ncbi.nlm.nih.gov
Background Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.
H Yokouchi, K Yamazaki, I Kinoshita, J Konishi… - BMC Cancer, 2007 - go.gale.com
Background Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
[PDF][PDF] Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
H Yokouchi, K Yamazaki, I Kinoshita, J Konishi… - BMC Cancer, 2007 - cyberleninka.org
Background: Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
[HTML][HTML] Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
H Yokouchi, K Yamazaki, I Kinoshita… - BMC …, 2007 - bmccancer.biomedcentral.com
Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase inhibitor, has a
certain efficacy against non-small cell lung cancer (NSCLC). Several predictive factors of …
certain efficacy against non-small cell lung cancer (NSCLC). Several predictive factors of …
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
H Yokouchi, K Yamazaki, I Kinoshita… - BMC …, 2007 - pubmed.ncbi.nlm.nih.gov
Background Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.
H Yokouchi, K Yamazaki, I Kinoshita, J Konishi… - BMC …, 2007 - search.ebscohost.com
Background: Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
[PDF][PDF] Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
H Yokouchi, K Yamazaki, I Kinoshita, J Konishi… - BMC Cancer, 2007 - researchgate.net
Background: Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
[PDF][PDF] Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
H Yokouchi, K Yamazaki, I Kinoshita, J Konishi… - BMC Cancer, 2007 - core.ac.uk
Background: Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …